Astellas Pharma is rolling up its sleeves for a domestic PIIb trial of its ASP0456 (development code; linaclotide), a treatment for constipation-predominant irritable bowel syndrome (IBS). With its once-promising proprietary drug for diarrhea-predominant IBS, Irribow (ramosetron), facing an uphill battle…
To read the full story
BUSINESS
- Takeda Wins Approval for Liquid Kenketu Glovenin-I 10%; Overseas-Derived Version Already Launched
February 12, 2026
- FDA Rejects Regenxbio/Nippon Shinyaku’s MPS II Gene Therapy
February 12, 2026
- Celltrion to Launch Japan’s First Actemra Biosimilar in Late April
February 12, 2026
- J&J Files Tecvayli/Darzquro Combo for MM in Japan
February 12, 2026
- Takeda’s Narcolepsy Drug Accepted for US FDA Review
February 12, 2026
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…





